110 related articles for article (PubMed ID: 7740849)
1. [The prognostic value of cathepsin D in endometrial carcinoma].
Köhler U; Langanke D; Sorger D; Martin R; Bilek K
Zentralbl Gynakol; 1995; 117(3):148-52. PubMed ID: 7740849
[TBL] [Abstract][Full Text] [Related]
2. [Rate of proliferation as a prognostic criterion in endometrial carcinoma--an immunohistochemical analysis with the monoclonal antibody KI-S1].
Backe J; Gassel AM; Müller T; Schön S; Kaesemann H
Zentralbl Gynakol; 1997; 119(7):334-42. PubMed ID: 9340973
[TBL] [Abstract][Full Text] [Related]
3. [Cathepsin D in primary breast cancer in correlation with various prognostic factors].
Rempen A; Caffier H
Geburtshilfe Frauenheilkd; 1991 Apr; 51(4):272-5. PubMed ID: 1650323
[TBL] [Abstract][Full Text] [Related]
4. Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.
Falcón O; Chirino R; León L; López-Bonilla A; Torres S; Fernández L; García-Hernández JA; Valerón PF; Díaz-Chico JC
Br J Cancer; 1999 Feb; 79(3-4):570-6. PubMed ID: 10027332
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
6. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
7. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
9. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
10. The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.
Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; Mychalczak BR; McKee B; Hoskins WJ; Barakat RR
Cancer; 2002 Jul; 95(2):316-21. PubMed ID: 12124832
[TBL] [Abstract][Full Text] [Related]
11. May cathepsin D immunoreactivity be used as a prognostic factor in endometrial carcinomas? A comparative immunohistochemical study.
Saygili U; Koyuncuoglu M; Altunyurt S; Guclu S; Uslu T; Erten O
Gynecol Oncol; 2001 Oct; 83(1):20-4. PubMed ID: 11585409
[TBL] [Abstract][Full Text] [Related]
12. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
13. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
14. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma.
Nazeer T; Malfetano JH; Rosano TG; Ross JS
Am J Clin Pathol; 1992 Jun; 97(6):764-9. PubMed ID: 1595596
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
Liebert A; Quietzsch D; Beier L
Anticancer Res; 1999; 19(4A):2571-6. PubMed ID: 10470197
[TBL] [Abstract][Full Text] [Related]
16. [Estrogen and progesterone receptors as prognostic markers in endometrial carcinoma].
Gorchev G; Milkov V
Akush Ginekol (Sofiia); 1992; 31(2):32-3. PubMed ID: 1342555
[TBL] [Abstract][Full Text] [Related]
17. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients.
Wang X; Huang Z; Di W; Lin Q
Arch Gynecol Obstet; 2005 Jul; 272(2):136-41. PubMed ID: 15666177
[TBL] [Abstract][Full Text] [Related]
18. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
[TBL] [Abstract][Full Text] [Related]
19. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker.
Devetzi M; Scorilas A; Tsiambas E; Sameni M; Fotiou S; Sloane BF; Talieri M
Gynecol Oncol; 2009 Mar; 112(3):531-6. PubMed ID: 19110306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
